SynapDx Corporation and Illumina Enter Into Strategic Relationship for
Collaboration to Also Evaluate Joint Initiatives in Pediatric Neurodevelopment
LEXINGTON, Mass. -- March 6, 2013
SynapDx Corporation and Illumina, Inc. have formed an alliance joining
SynapDx’s proprietary autism technologies with Illumina’s sequencing platform
to develop early detection tools for autism spectrum disorders (ASDs). The
companies will also leverage their joint expertise to broadly evaluate other
opportunities in neurodevelopment.
“SynapDx and Illumina share a vision of better pediatric care through the use
of advanced molecular assays and sequencing technologies,” said Stanley
Lapidus, SynapDx’s CEO. “We look forward to broadly collaborating on multiple
SynapDx’s breakthrough blood-based autism spectrum disorder (ASD) test,
currently in clinical development, is designed to help clinicians identify
children with autism earlier than they do today.
“Our relationship with SynapDx highlights our commitment to collaborating with
cutting-edge companies doing truly innovative work that will improve patient
care,” said Matt Posard, senior vice president and general manager of
Illumina's Translational and Consumer Genomics business. “SynapDx’s commitment
to the early detection of autism makes our work together truly meaningful, and
we are pleased to join forces in this important effort.”
About SynapDx Corp.
SynapDx is a private company developing laboratory diagnostic services for
autism and neurodevelopmental disorders, with the initial goal of enabling
earlier detection of autism spectrum disorders (ASDs). The company
collaborates with ASD experts at leading institutions. SynapDx was founded in
2010 and is based in Lexington, Mass. SynapDx’s investors include North Bridge
Venture Partners, General Catalyst Partners and LabCorp.
Lois Paul and Partners
Susan McCarron, 617-986-5767
Press spacebar to pause and continue. Press esc to stop.